Markets

Epinex market research has identified markets of more than 13 million diabetics in the U.S. alone who would immediately benefit from the G1A™ Rapid Diabetes Monitoring Index Test.

IMMEDIATE TARGET MARKETS FOR THE G1A™ TEST

Gestational Diabetes (GDM)

• 3.4 million pregnancies/year; 135,000 cases of GDM/year.
• Medical authorities call for ALL pregnant women to be screened for GDM.
• Rapid test for short-term glycation currently does not exist.
• Point-of-Care Symposium recommends glycated albumin as the test of choice for GDM.
• G1A™ is a tool to screen all expectant mothers and monitor GDM.

Diabetics on Hemodialysis

• Approximately 200,000 diabetics are on hemodialysis.
• Diabetes is the leading cause of end-stage renal disease (ESRD).
• Hemodialysis drug interactions cause HbA1c test to yield questionable results.
• Glycated albumin is a more accurate measure of glycation.
• G1A™ testing will more accurately reflect glycemic control.

Red Cell Disorders (hemoglobinopathy)

• Approximately 560,000 type 2 diabetics suffer from red blood cell disorders.
• Because of its dependence on red blood cells, HbA1c can yield false high/low results with potential for misdiagnosis or under treatment.
• The G1A™ test measures glycated albumin, which is unaffected by RBC disorders.

Geriatric patients with diabetes

• Approximately nine million diabetics are over 65.
• Diabetes is the 6th most common cause of death among the elderly.
• Most do not meet short-term glucose goals.
• The monthly G1A™ test is an early intervention tool that can improve compliance and quality of life.